Skip to content

Defeat Cancer by Detecting it Early

EarlyDiagnostics (EarlyDx) is devoted to providing accurate, affordable, and non-invasive liquid biopsy tests for early cancer detection and precision medicine.


Big Data for Better Diagnosis

We have developed a blood test, CancerRadar, which is highly accurate and sensitive in detecting and locating cancer. In addition, we developed a One-Stop Shop bioinformatics solution, EarlyDx-Cloud, to help many diagnostic companies offer liquid biopsy tests for cancer detection, therapy selection, and treatment monitoring.

how it works

The Technology behind Cancer Detection

Discover our experimental and computational innovations.

cfMethyl-seq technology – a novel NGS solution to profile the cfDNA methylome.


A novel computational tool to accurately call mutations directly from blood.


Non-invasive monitoring of cancer MRD, Recurrence, and Evolution.


A “One-Stop Shop” bioinformatics solution for liquid biopsy.


Our technologies are empowered by Innovation.

Our Team

Our Experts Are Waiting For You

We bring the right people together to challenge established thinking and drive transformation.

Latest News

Read the latest news and blog posts from EarlyDx.

June 2022

EarlyDx announced appointment of Guanghui Hu as co-CEO.

May 2022

EarlyDx published cfTrack: Non-invasive monitoring of cancer MRD, Recurrence, and Evolution in Clinical Cancer Research.

Sep 2021

EarlyDx Awarded an NIH SBIR Phase I Contract for Cloud Platform Development.